Abstract
Although multiple clinical trials have demonstrated the efficacy of crizotinib in the treatment of anaplastic lymphoma kinase (ALK) / c-ros oncogene 1 (ROS1) fusion advanced non-small-cell lung cancer (NSCLC), the under-represented populations, as well as the complexities and diversity of day-to-day cancer care are still to be complemented.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
